70 results about "Eriodictyol" patented technology

A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, and a combination thereof. A UGT2B enhancer capable of enhancing a clearance rate of morphine-like analgesic agents, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (−)-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof.

The invention discloses a method for producing eriodictyol by reforming escherichia coli in metabolic engineering, belonging to the field of metabolic engineering. The step of transforming naringenin into the eriodictyol is successfully realized through a gene engineering technology by carrying out fusion expression on two genes, namely a flavone 3' hydroxylase gene tF3'H with a membrane binding sequence cut and a P450 reductase gene tCPR, in escherichia coli. A tyrosine ammonia lyase gene TAL from R.glutinis, 4-coumarate:coenzyme A ligase gene 4CL from P.crispum, a chalcone synthase gene CHS from P.hybrida and a chalcone isomerase gene CHI from M.sativa are simultaneously expressed to realize that naringenin is directly produced through tyrosine, so that an engineered strain for directly producing eriodictyol through tyrosine is established. According to the method, in order to increase the output of eriodictyol, an acetokinase ackA gene contained in an escherichia coli genome is removed by being knocked, an acetyl coenzyme A synthetase gene acs and an acetyl coenzyme A carboxylase gene ACC are excessively expressed, and the output of eriodictyol can finally reach 106.7 mg / L.

The invention provides semisynthesis luteolin preparation new process. The process includes a first step of hydrolyzing hesperidin to obtain hesperetin, a second step of demethylating the hesperetin to obtain eriodictyol, and a third step of dehydrogenizing the eriodictyol to obtain the luteolin. Compared with the prior art that the hesperidin is firstly dehydrogenized and then hydrolyzed, the process enables the iodine using amount to be greatly reduced, and production cost is low. The invention further provides technology for preparing the eriodictyol.

This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin, 3-Phenylpropyl Acetate, Oleanolic acid, ursolic acid, β-Myrcene, cinnamic acid, Luteolin-7-Glucoside, Liquiritin, (+)Limonene, Homoorientin, Swertiamarin, Embelin, Daidzein, Poncirin, (−)-Epicatechin, ergosterol. These natural products can be used to enhance the bioavailability of therapeutic agents (drugs).

The invention provides a method to extract dihydroquercetin from roots of a particular tree species Larix olgensis. The method includes the steps of selection of raw materials, enzyme treatment, extraction, concentration, hydrolysis, extraction, recrystallization, and spray drying. Composition of the flavonoid compounds in the extractive of Larix olgensis is confirmed by HPLC-MS, and the extractive mainly comprises dihydroquercetin, and others compounds of aromadendrin, eriodictyol, quercetin and kaempferol. In vitro experiments prove that dihydroquercetin extractive form Larix olgensis has strong inhibitory effects on tyrosinase activity, and the effect of scavenging DPPH free radicals. Animal in vivo experiment demonstrates that the Larix olgensis extractive has good recovery effect on carbon tetrachloride induced liver injury.

The present invention relates generally to a genetic sequence encoding a polypeptide having flavonoid 3′,5′-hydroxylase (F3′5′H) activity and to the use of the genetic sequence and / or its corresponding polypeptide thereof inter alia to manipulate color in flowers or parts thereof or in other plant tissue. More particularly, the F3′5′H has the ability to modulate dihydrokaempferol (DHK) metabolism as well as the metabolism of other substrates such as dihydroquercetin (DHQ), naringenin and eriodictyol. Even more particularly, the present invention provides a genetic sequence encoding a polypeptide having F3′5′H activity when expressed in rose or gerbera or botanically related plants. The instant invention further relates to antisense and sense molecules or RNAi-inducing molecules corresponding to all or part of the subject genetic sequence or a transcript thereof. The present invention further relates to promoters which operate efficiently in plants such as rose, gerbera or botanically related plants.

The present invention relates generally to a genetic sequence encoding a polypeptide having flavonoid 3′,5′-hydroxylase (F3′5′H) activity and to the use of the genetic sequence and / or its corresponding polypeptide thereof inter alia to manipulate color in flowers or parts thereof or in other plant tissue. More particularly, the F3′5′H has the ability to modulate dihydrokaempferol (DHK) metabolism as well as the metabolism of other substrates such as dihydroquercetin (DHQ), naringenin and eriodictyol. Even more particularly, the present invention provides a genetic sequence encoding a polypeptide having F3′5′H activity when expressed in rose or gerbera or botanically related plants. The instant invention further relates to antisense and sense molecules or RNAi-inducing molecules corresponding to all or part of the subject genetic sequence or a transcript thereof. The present invention further relates to promoters which operate efficiently in plants such as rose, gerbera or botanically related plants.

The invention provides novel flavone hydroxylase, a microorganism for synthesizing a flavone C-glycoside compound and an application of the novel flavone hydroxylase. The inventor clones to obtain novel flavone hydroxylase PhF2H and PhF3'H, and the novel flavone hydroxylase PhF2H and PhF3'H belongs to cytochrome P450 hydroxylase and has a function of hydroxylating a specific position of the compound. Furthermore, the inventor efficiently synthesizes the flavone C-glycoside compound, such as orientin, isoorientin, vitexin and isovitexin, and related intermediates such as eriodictyol, 2-hydroxynaringenin and the like in a synthetic route of the flavone C-glycoside compound in an artificial recombinant expression system by modifying the enzyme and combining with the assembly of a synthetic route of C-glycoside glycosyltransferase and a flavone precursor.

The invention provides O-methyltransferase participating in citrus peel flavone synthesis and a coding gene and application thereof. The expression level of CitOMT1 is positively correlated with the accumulation of polymethoxylated flavones in a fruit development process of Citrus reticulata cv. Suavissima; in vitro enzyme activity assays indicate that the O-methyltransferase can be applied to catalyze specific site methylation of flavones, in particular to catalyze quercetin to produce quercetin 3',4' dimethyl ester, catalyze luteolin to produce chrysoeriol, catalyze eriodictyol to produce hesperidin and homoeriodictyol, catalyze baicalein to produce oroxylin A, and catalyze 7,8-dihydroxyflavone to produce 7-hydroxy-8-methoxy flavone. The enzyme activity assays have simple reaction conditions, do not require additional metal ions, and have high application value and research prospects.

The invention discloses a method for obtaining eriodictyol by biologically transforming naringenin. The method comprises the following steps: preparing co-expressed recombinant bacillus coli at first; then carrying out preculture and enlarge culture on the recombinant bacillus coli; and after collecting thalli, biologically transforming the naringenin by using the thalli. The naringenin is transformed by a recombinant bacillus coli transformant, the eriodictyol as a single compound is generated in an orientated manner, hybridity of the product is reduced, meanwhile, steps of product separation and extraction are simplified, and difficulty in obtaining of the eriodictyol is reduced.

The present invention discloses a method for simultaneous determination of naringenin and eriodictyol content in fresh-cut water chestnut etiolation organization, and the method comprises the six steps of preparation of a standard naringenin stock solution, preparation of a standard eriodictyol stock solution, preparation of a mixed naringenin and eriodictyol standard solution, production of a standard curve, preparation of a to-be-tested sample solution, and calculation of naringenin and eriodictyol content in a fresh-cut water chestnut etiolation organization sample. According to the method, the naringenin and the eriodictyol in the fresh-cut water chestnut etiolation organization can be effectively separated, the naringenin and eriodictyol content in the fresh-cut water chestnut etiolation organization can be simultaneously determined, the method is simple, fast, accurate and reliable, and can exclude interference produced by other substance chromatography and other substances contained in the fresh-cut water chestnut etiolation organization.

The invention discloses a flavone 3 beta-hydroxylase mutant with improved catalytic activity and application thereof, and belongs to the technical field of gene engineering. According to the invention, the flavonoid 3beta-hydroxylase mutant capable of increasing the eriodictyol yield is obtained by mutating flavonoid 3beta-hydroxylase from silybum marianum and screening. When the flavone 3 beta-hydroxylase mutant is applied to production of eriodictyol, the eriodictyol yield can be respectively increased to 1017.8 mg / L and 1046.5 mg / L from 805.6 mg / L of an original strain at a shake flask level, and is respectively increased by 26.3% and 29.9% compared with the original flavone 3 beta-hydroxylase yield.

The invention discloses application of silybum marianum-derived flavonoid 3 beta-hydroxylase and coenzyme thereof, and belongs to the field of gene and metabolic engineering. According to the invention, SmF3 'H and SmCPR with flavonoid 3'-hydroxylase functions are obtained and verified from silybum marianum, and have the capability of catalyzing naringenin to synthesize eriodictyol. Compared withthe common GhF3 'H and CrCPR, the SmF3' H and SmCPR used in the method have the advantage that the yield of eriodictyol generated by converting naringenin can be increased by 17.0 percent under the same culture condition. On the basis, promoters with different intensities are used for regulating SmF3 'H and SmCPR, the yield of eriodictyol is further increased, the yield of eriodictyol can reach 805.6 mg / L in a 250 mL shake flask, and the yield is increased by 302.8% compared with the reported maximum yield of 200 mg / L. The flavonoid 3 beta-hydroxylase from silybum marianum and coenzyme thereofhave good performance of converting naringenin to synthesize eriodictyol, so that the flavonoid 3 beta-hydroxylase from silybum marianum and coenzyme thereof have wide application prospect.

The invention discloses a method for detecting eriodictyol with high flux and belongs to the technical field of synthetic biologics. A developing agent used in the method is sodium hydroxide or potassium hydroxide, after developing treatment, eriodictyol is purple, the higher the concentration is, the darker the purple is, the longer the developing is, the longer the standing time is, the color isalso darkened, the reaction is completed within 5 minutes generally, and high-yield strains can be still selected by using a visual method directly even in the presence of an interfering substance naringenin. The reaction liquid can be further detected by using a microplate reader. In a water solution, NaOH is recommended for treatment, the optimal detection wavelength is 550-580nm, in a colorless synthesis culture medium, KOH (Potassium Hydroxide) is recommended for treatment, and the optimal detection wavelength is 560-570nm. The method is simple, convenient and efficient, good in interference prevention, high in precision, low in time and labor cost and applicable to high-flux screening of high yield strains of eriodictyol.

The present invention relates to the production of eriodictyol via bioconversion.

The invention belongs to the field of drugs or health care products, and particularly provides application of single use of a flavonoid small molecule compound or combination use of the flavonoid small molecule compound and other drugs in preparing a drug for inhibiting pancreatic lipase activity. The flavonoid small molecule compound is eriodictyol. The eriodictyol inhibits the absorption of triglyceride in food by inhibiting the pancreatic lipase activity, and has a better effect on preventing / treating obesity. The disclosed eriodictyol is derived from peanut shells, can better inhibit the pancreatic lipase activity, and provides a basis and reference for the development of drugs and health care products for preventing the obesity. Therefore, the disclosed natural substance eriodictyol as a lipid-lowering health care product has broad development prospects.

The invention provides an eriodictyol synthesis method. According to the eriodictyol synthesis method, isovanillin and 2,4,6-trihydroxyacetophenone are selected as starting materials, and eriodictyol is obtained through the following five steps: firstly, performing MOMCl protection on a hydroxyl of isovanillin; secondly, performing MOMCl protection on a hydroxyl of 2,4,6-trihydroxyacetophenone; thirdly, performing an aldol condensation reaction to generate chalcone; fourthly, performing Michael addition and cyclization; finally, carrying out MOM deprotection to obtain eriodictyol of which the total yield is 50-65%. As isovanillin and 2,4,6-trihydroxyacetophenone are selected as the starting materials, the eriodictyol synthesis method is high in yield and suitable for industrialized production.

The invention relates to an application of eriodictyol in preparation of a medicine for treating the AD (alzheimer's disease). A beta 25-35 damaged PC-12 cell is taken as an in-vitro model of the AD,estradiol is taken as positive control, the anti-AD effect of eriodictyol and the action mechanism producing the effect are researched from the view of anti-apoptosis, a solid experimental foundationand theoretical foundation are laid for treatment of the AD and other nervous centralis degenerative diseases by use of phytoestrogen from the molecular level, and the eriodictyol has important actualapplication value.

The invention discloses a flavone 3 beta-hydroxylase reductase coenzyme mutant and application thereof, and belongs to the technical field of gene engineering. The flavonoid 3 beta-hydroxylase reductase coenzyme mutant capable of improving catalytic and production performance is obtained by mutating flavonoid 3 beta-hydroxylase reductase coenzyme, and the obtained mutant assists flavone 3 beta-hydroxylase reductase in conversion in saccharomyces cerevisiae, so that the eriodictyol content can be increased to 980.9 mg / L-1052.1 mg / L in comparison with the parent 805.6 mg / L; and the yield is increased by 21.8%-30.6%. Therefore, the flavone 3 beta-hydroxylase reductase coenzyme mutant obtained by the invention has a wide application prospect.

The invention discloses a method for producing eriodictyol by reforming escherichia coli in metabolic engineering, belonging to the field of metabolic engineering. The step of transforming naringenin into the eriodictyol is successfully realized through a gene engineering technology by carrying out fusion expression on two genes, namely a flavone 3' hydroxylase gene tF3'H with a membrane binding sequence cut and a P450 reductase gene tCPR, in escherichia coli. A tyrosine ammonia lyase gene TAL from R.glutinis, 4-coumarate:coenzyme A ligase gene 4CL from P.crispum, a chalcone synthase gene CHS from P.hybrida and a chalcone isomerase gene CHI from M.sativa are simultaneously expressed to realize that naringenin is directly produced through tyrosine, so that an engineered strain for directly producing eriodictyol through tyrosine is established. According to the method, in order to increase the output of eriodictyol, an acetokinase ackA gene contained in an escherichia coli genome is removed by being knocked, an acetyl coenzyme A synthetase gene acs and an acetyl coenzyme A carboxylase gene ACC are excessively expressed, and the output of eriodictyol can finally reach 106.7 mg / L.

A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin,β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, and a combination thereof. A UGT2B enhancer capable of enhancing a clearance rate of morphine-like analgesic agents, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (−)-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof.

The invention belongs to the field of food detection, and particularly relates to a method for detecting 5,7-dyhydroxy chromone, eriodictyol and luteolin which serve as main active ingredients in a peanut shell simultaneously. In the method, three active ingredients are detected by high performance liquid chromatography and by using octadecyl silane bonded silica gel as a filling agent and methanol and an aqueous gradient elution solvent as a mobile phase and regulating the pH value by acid; and sample introduction is performed once, and a chromatographic peak of each component is better separated to obtain the detection effect with high accuracy and repeatability. The method for detecting the 5,7-dyhydroxy chromone, the eriodictyol and the luteolin in the peanut shell is simple, easy andconvenient to operate, low in cost and high in efficiency, and is a shortcut for the quality control of the raw materials and products.

The invention provides a method for determining the content of active ingredients in Chinese honeylocust fruit, which adopts ultra-high performance liquid chromatography-mass spectrometry. The content of L-malic acid, protocatechuic aldehyde, protocatechuic acid, caffeic acid, scopoletin, liquiritigenin, apigenin, luteolin, eriodictyol, citrus aurantium, fustin, cryptochlorogenic acid, neochlorogenic acid, chlorogenic acid, vitexin, isovitexin, quercitrin, orientin and isoorientin in the Chinese honeylocust fruit can be rapidly detected. The method provided by the invention has the advantages of simple operation, high sensitivity, fast analysis speed and strong specificity, and can be used for quality control of Chinese honeylocust fruit.

This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin, 3-Phenylpropyl Acetate, Oleanolic acid, ursolic acid, β-Myrcene, cinnamic acid, Luteolin-7-Glucoside, Liquiritin, (+) Limonene, Homoorientin, Swertiamarin, Embelin, Daidzein, Poncirin, (−)-Epicatechin, ergosterol. These natural products can be used to enhance the bioavailability of therapeutic agents (drugs).

The invention discloses an application of polyphenol oxidase and a flavone synthesis method, and further limits the application of polyphenol oxidase in catalyzing oxidation of a compound with a structure as shown in a formula 1 to generate a compound with a structure as shown in a formula II or a formula III, and the amino acid sequence of the polyphenol oxidase is as shown in SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7 or SEQ ID NO.8. It is verified that the polyphenol oxidase can be used for converting eriodictyol into luteolin and 5,7-dihydroxychromone, and converting butin into 3',4',7-trihydroxyflavone and 7-hydroxy-4-benzopyrone; and the method is of great significance to research on a tomato flavone biosynthesis mechanism. The invention further verifies that the SlPPO F protein has very high thermal stability, and luteolin is synthesized by using escherichia coli engineering bacteria of the gene, thereby providing a new tool for developing microbial engineering and enzyme engineering.

The invention relates to compounds of formula (I) or the salts thereof, said compounds of formula (I) being selected from among the group consisting of homoeriodictyol (1), eriodictyol (2), hesperetin (3) and sterubin (4), for use in the treatment of an ailment which can be alleviated or prevented by influencing the serotonin level and the concentration of free fatty acids in the blood.

The present invention discloses an artemisia ordosica root extract and a preparation method and an application thereof. The preparation method of the artemisia ordosica root extract comprises the following steps: drying and crushing artemisia ordosica roots and adding an ethanol solution for ultrasonic extraction; then mixing each extract and conducting concentrating and drying to obtain an extract A; and (2) dissolving the extract A with distilled water, and sequentially conducting extraction with petroleum ether, ethyl acetate and n-butanol; and collecting an ethyl acetate layer extract, andconducting concentration under reduced pressure and drying to obtain a finished product. The artemisia ordosica root extract contains 50-90% of total flavonoids, and eriodictyol, isosakuranetin, naringenin, hydroxygenkwanin, genkwanin, acacetin, diosmetin, glycitein, isorhamnetin, morin and quercetin with the total content of more than 2%. The artemisia ordosica root extract can obviously reduceallergic rhinitis symptoms of guinea pigs, also reduces levels of inflammatory factors of histamine, ovalbumin specific IgE, IL-2 / 4 / 10, IFN-gamma, ICam-1, etc. in serum of the guinea pigs, and can also reduce infiltration of eosinophilic granulocyte of nasal mucosa of nasal cavities of the guinea pigs.

The invention provides an in-vitro enzyme activity application of citrus-oxygen-methyltransferase CitOMT2. The CitOMT2 recombinant protein obtained through prokaryotic expression can efficiently catalyze the methylation of various flavonoids at specific sites in vitro. That is to say, luteolin, quercetin, 3-methylquercetin,eriodictyol, quercetin and myricetin are catalyzed to be methylated at thehydroxyl group in the meta-position of a B ring to generate corresponding 3'or 3' / 5' methylated derivatives. Baicalein is catalyzed to be methylated at the 7 site of hydroxy to generate 7-methylbaicalein. According to the invention, an oxygen-methyltransferase CitOMT2 capable of catalyzing the 3' / 5' / 7 sites of flavonoids is identified for the first time. The multi-site catalytic property of CitOMT2 helps to quickly and accurately expand the diversity of O-methylated flavonoids, and the oxygen-methyltransferase CitOMT2has broad prospects and application value.